A detailed history of Cresset Asset Management, LLC transactions in United Therapeutics Corp stock. As of the latest transaction made, Cresset Asset Management, LLC holds 9,390 shares of UTHR stock, worth $3.42 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
9,390
Previous 8,932 5.13%
Holding current value
$3.42 Million
Previous $2.85 Million 18.24%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$311.04 - $363.55 $142,456 - $166,505
458 Added 5.13%
9,390 $3.36 Million
Q2 2024

Aug 14, 2024

BUY
$228.26 - $319.04 $207,260 - $289,688
908 Added 11.32%
8,932 $2.85 Million
Q1 2024

May 15, 2024

BUY
$210.76 - $249.51 $234,365 - $277,455
1,112 Added 16.09%
8,024 $1.84 Million
Q4 2023

Feb 14, 2024

BUY
$214.88 - $256.94 $242,169 - $289,571
1,127 Added 19.48%
6,912 $1.52 Million
Q3 2023

Nov 14, 2023

BUY
$211.82 - $248.24 $154,840 - $181,463
731 Added 14.46%
5,785 $1.31 Million
Q2 2023

Aug 14, 2023

BUY
$205.19 - $232.99 $1.04 Million - $1.18 Million
5,054 New
5,054 $1.12 Million
Q1 2022

May 16, 2022

SELL
$166.16 - $213.96 $374,524 - $482,265
-2,254 Closed
0 $0
Q4 2021

Feb 10, 2022

BUY
$184.32 - $216.08 $47,185 - $55,316
256 Added 12.81%
2,254 $488,000
Q3 2021

Nov 15, 2021

BUY
$179.86 - $214.88 $3,597 - $4,297
20 Added 1.01%
1,998 $368,000
Q2 2021

Aug 10, 2021

SELL
$170.47 - $211.93 $170 - $211
-1 Reduced 0.05%
1,978 $355,000
Q1 2021

May 12, 2021

BUY
$153.94 - $174.85 $304,647 - $346,028
1,979 New
1,979 $331,000
Q2 2019

Aug 12, 2019

SELL
$76.06 - $120.81 $48,526 - $77,076
-638 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$107.15 - $126.84 $67,290 - $79,655
628 Added 6280.0%
638 $75,000
Q4 2018

May 21, 2019

BUY
$101.4 - $128.73 $1,014 - $1,287
10 New
10 $1,000

Others Institutions Holding UTHR

About UNITED THERAPEUTICS Corp


  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $16.6B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track This Portfolio

Track Cresset Asset Management, LLC Portfolio

Follow Cresset Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cresset Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cresset Asset Management, LLC with notifications on news.